Real-World check: can a targeted ovarian cancer drug deliver outside clinical trials?
NCT ID NCT07690332
First seen Jul 08, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study tracks the safety and effectiveness of mirvetuximab soravtansine (MIRV), a drug that targets a protein called folate receptor alpha on cancer cells, in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. Researchers will observe 400 patients receiving MIRV as part of their routine care, focusing on side effects and how well the drug shrinks tumors. The goal is to see if the drug's benefits seen in clinical trials hold up in real-world settings, especially in Chinese patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mirvetuximab soravtansine (MIRV, Elahere)
- What this could lead to
- If successful, this study could confirm that MIRV works well and is safe in everyday clinical practice, especially for Chinese patients with advanced ovarian cancer.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. Side effects like eye problems, infusion reactions, and gastrointestinal issues are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a custom mRNA vaccine keep ovarian cancer from coming back?
- Can a cancer pill keep working outside the lab? a Real-World test begins
- Can a Patient's own immune cells be supercharged to fight ovarian cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?